Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study

Abstract Antibiotics that inhibit bacterial protein or nucleic acid synthesis and function can exert an off-target action on mitochondria (mitotoxic antibiotics), making actively dividing mammalian cells dependent on uridine and pyruvate supplementation. Based on this rationale, we carried out, for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefano Battaglia, Stefania De Santis, Monica Rutigliano, Fabio Sallustio, Angela Picerno, Maria Antonia Frassanito, Ingo Schaefer, Angelo Vacca, Antonio Moschetta, Peter Seibel, Michele Battaglia, Gaetano Villani
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/175fce9d945345579c3dc0579ab7593b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:175fce9d945345579c3dc0579ab7593b
record_format	dspace
spelling	oai:doaj.org-article:175fce9d945345579c3dc0579ab7593b2021-12-02T17:13:27ZUridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study10.1038/s41598-021-91559-82045-2322https://doaj.org/article/175fce9d945345579c3dc0579ab7593b2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91559-8https://doaj.org/toc/2045-2322Abstract Antibiotics that inhibit bacterial protein or nucleic acid synthesis and function can exert an off-target action on mitochondria (mitotoxic antibiotics), making actively dividing mammalian cells dependent on uridine and pyruvate supplementation. Based on this rationale, we carried out, for the first time, a randomized pilot study in 55 patients with asymptomatic bacteriuria or positive sperm culture, each treated with a single mitotoxic antibiotic with or without oral supplementation of uridine + pyruvate (Uripyr, Mitobiotix, Italy). The in vivo and ex vivo data show a a 3.4-fold higher value in the differential (before and after the antibiotic treatment) lymphocytes count and a 3.7-fold increase in the percentage of dividing T cells, respectively, in the Uripyr vs the control group. Our findings lay the groundwork to enhance the synergy between antibiotics and the immune system in order to optimize the administration protocols and widen the application potentials of antibiotic therapies as well as to re-evaluate old “forgotten” molecules to fight bacterial infections in the antibiotics resistance era.Stefano BattagliaStefania De SantisMonica RutiglianoFabio SallustioAngela PicernoMaria Antonia FrassanitoIngo SchaeferAngelo VaccaAntonio MoschettaPeter SeibelMichele BattagliaGaetano VillaniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Stefano Battaglia Stefania De Santis Monica Rutigliano Fabio Sallustio Angela Picerno Maria Antonia Frassanito Ingo Schaefer Angelo Vacca Antonio Moschetta Peter Seibel Michele Battaglia Gaetano Villani Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
description	Abstract Antibiotics that inhibit bacterial protein or nucleic acid synthesis and function can exert an off-target action on mitochondria (mitotoxic antibiotics), making actively dividing mammalian cells dependent on uridine and pyruvate supplementation. Based on this rationale, we carried out, for the first time, a randomized pilot study in 55 patients with asymptomatic bacteriuria or positive sperm culture, each treated with a single mitotoxic antibiotic with or without oral supplementation of uridine + pyruvate (Uripyr, Mitobiotix, Italy). The in vivo and ex vivo data show a a 3.4-fold higher value in the differential (before and after the antibiotic treatment) lymphocytes count and a 3.7-fold increase in the percentage of dividing T cells, respectively, in the Uripyr vs the control group. Our findings lay the groundwork to enhance the synergy between antibiotics and the immune system in order to optimize the administration protocols and widen the application potentials of antibiotic therapies as well as to re-evaluate old “forgotten” molecules to fight bacterial infections in the antibiotics resistance era.
format	article
author	Stefano Battaglia Stefania De Santis Monica Rutigliano Fabio Sallustio Angela Picerno Maria Antonia Frassanito Ingo Schaefer Angelo Vacca Antonio Moschetta Peter Seibel Michele Battaglia Gaetano Villani
author_facet	Stefano Battaglia Stefania De Santis Monica Rutigliano Fabio Sallustio Angela Picerno Maria Antonia Frassanito Ingo Schaefer Angelo Vacca Antonio Moschetta Peter Seibel Michele Battaglia Gaetano Villani
author_sort	Stefano Battaglia
title	Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
title_short	Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
title_full	Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
title_fullStr	Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
title_full_unstemmed	Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
title_sort	uridine and pyruvate protect t cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/175fce9d945345579c3dc0579ab7593b
work_keys_str_mv	AT stefanobattaglia uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT stefaniadesantis uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT monicarutigliano uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT fabiosallustio uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT angelapicerno uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT mariaantoniafrassanito uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT ingoschaefer uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT angelovacca uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT antoniomoschetta uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT peterseibel uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT michelebattaglia uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy AT gaetanovillani uridineandpyruvateprotecttcellsproliferativecapacityfrommitochondrialtoxicantibioticsaclinicalpilotstudy
_version_	1718381306237157376

Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study

Ejemplares similares